317 related articles for article (PubMed ID: 33848310)
1. Puerarin dry powder inhaler formulations for pulmonary delivery: Development and characterization.
Rashid MA; Muneer S; Wang T; Alhamhoom Y; Rintoul L; Izake EL; Islam N
PLoS One; 2021; 16(4):e0249683. PubMed ID: 33848310
[TBL] [Abstract][Full Text] [Related]
2. Development and characterization of meropenem dry powder inhaler formulation for pulmonary drug delivery.
Muneer S; Wang T; Rintoul L; Ayoko GA; Islam N; Izake EL
Int J Pharm; 2020 Sep; 587():119684. PubMed ID: 32736016
[TBL] [Abstract][Full Text] [Related]
3. Protection of hydrophobic amino acids against moisture-induced deterioration in the aerosolization performance of highly hygroscopic spray-dried powders.
Yu J; Chan HK; Gengenbach T; Denman JA
Eur J Pharm Biopharm; 2017 Oct; 119():224-234. PubMed ID: 28655664
[TBL] [Abstract][Full Text] [Related]
4. Inhaled Edoxaban dry powder inhaler formulations: Development, characterization and their effects on the coagulopathy associated with COVID-19 infection.
Rashid MA; Muneer S; Mendhi J; Sabuj MZR; Alhamhoom Y; Xiao Y; Wang T; Izake EL; Islam N
Int J Pharm; 2021 Oct; 608():121122. PubMed ID: 34560207
[TBL] [Abstract][Full Text] [Related]
5. L-Leucine as an excipient against moisture on in vitro aerosolization performances of highly hygroscopic spray-dried powders.
Li L; Sun S; Parumasivam T; Denman JA; Gengenbach T; Tang P; Mao S; Chan HK
Eur J Pharm Biopharm; 2016 May; 102():132-41. PubMed ID: 26970252
[TBL] [Abstract][Full Text] [Related]
6. Excipient Interactions in Glucagon Dry Powder Inhaler Formulation for Pulmonary Delivery.
Rashid MA; Elgied AA; Alhamhoom Y; Chan E; Rintoul L; Allahham A; Islam N
Pharmaceutics; 2019 May; 11(5):. PubMed ID: 31052466
[TBL] [Abstract][Full Text] [Related]
7. Development of a Carrier Free Dry Powder Inhalation Formulation of Ketotifen for Pulmonary Drug Delivery.
Azari F; Ghanbarzadeh S; Safdari R; Yaqoubi S; Adibkia K; Hamishehkar H
Drug Res (Stuttg); 2020 Jan; 70(1):26-32. PubMed ID: 31533157
[TBL] [Abstract][Full Text] [Related]
8. Physicochemical stability and aerosolization performance of dry powder inhalation system containing ciprofloxacin hydrochloride.
Karimi K; Katona G; Csóka I; Ambrus R
J Pharm Biomed Anal; 2018 Jan; 148():73-79. PubMed ID: 28965047
[TBL] [Abstract][Full Text] [Related]
9. Investigations on the Mechanism of Magnesium Stearate to Modify Aerosol Performance in Dry Powder Inhaled Formulations.
Jetzer MW; Schneider M; Morrical BD; Imanidis G
J Pharm Sci; 2018 Apr; 107(4):984-998. PubMed ID: 29247741
[TBL] [Abstract][Full Text] [Related]
10. Preparation and Evaluation of Surface Modified Lactose Particles for Improved Performance of Fluticasone Propionate Dry Powder Inhaler.
Singh DJ; Jain RR; Soni PS; Abdul S; Darshana H; Gaikwad RV; Menon MD
J Aerosol Med Pulm Drug Deliv; 2015 Aug; 28(4):254-67. PubMed ID: 25517187
[TBL] [Abstract][Full Text] [Related]
11. Improved Physical Stability and Aerosolization of Inhalable Amorphous Ciprofloxacin Powder Formulations by Incorporating Synergistic Colistin.
Shetty N; Ahn P; Park H; Bhujbal S; Zemlyanov D; Cavallaro A; Mangal S; Li J; Zhou QT
Mol Pharm; 2018 Sep; 15(9):4004-4020. PubMed ID: 30028947
[TBL] [Abstract][Full Text] [Related]
12. Aerosolization characteristics of dry powder inhaler formulations for the excipient enhanced growth (EEG) application: effect of spray drying process conditions on aerosol performance.
Son YJ; Worth Longest P; Hindle M
Int J Pharm; 2013 Feb; 443(1-2):137-45. PubMed ID: 23313343
[TBL] [Abstract][Full Text] [Related]
13. Heat-Stable Dry Powder Oxytocin Formulations for Delivery by Oral Inhalation.
Fabio K; Curley K; Guarneri J; Adamo B; Laurenzi B; Grant M; Offord R; Kraft K; Leone-Bay A
AAPS PharmSciTech; 2015 Dec; 16(6):1299-306. PubMed ID: 25776985
[TBL] [Abstract][Full Text] [Related]
14. Design, physicochemical characterization, and optimization of organic solution advanced spray-dried inhalable dipalmitoylphosphatidylcholine (DPPC) and dipalmitoylphosphatidylethanolamine poly(ethylene glycol) (DPPE-PEG) microparticles and nanoparticles for targeted respiratory nanomedicine delivery as dry powder inhalation aerosols.
Meenach SA; Vogt FG; Anderson KW; Hilt JZ; McGarry RC; Mansour HM
Int J Nanomedicine; 2013; 8():275-93. PubMed ID: 23355776
[TBL] [Abstract][Full Text] [Related]
15. The influence of storage relative humidity on aerosolization of co-spray dried powders of hygroscopic kanamycin with the hydrophobic drug rifampicin.
Momin MAM; Tucker IG; Das SC
Drug Dev Ind Pharm; 2019 Jul; 45(7):1205-1213. PubMed ID: 30990097
[TBL] [Abstract][Full Text] [Related]
16. Role of dispersion enhancer selection in the development of novel tratinterol hydrochloride dry powder inhalation formulations.
Liu T; Tong S; Liao Q; Pan L; Cheng M; Rantanen J; Cun D; Yang M
Int J Pharm; 2023 Mar; 635():122702. PubMed ID: 36773729
[TBL] [Abstract][Full Text] [Related]
17. Inhalable lactose-based dry powder formulations of low molecular weight heparin.
Bai S; Gupta V; Ahsan F
J Aerosol Med Pulm Drug Deliv; 2010 Apr; 23(2):97-104. PubMed ID: 19778265
[TBL] [Abstract][Full Text] [Related]
18. Low powder mass filling of dry powder inhalation formulations.
Eskandar F; Lejeune M; Edge S
Drug Dev Ind Pharm; 2011 Jan; 37(1):24-32. PubMed ID: 20738180
[TBL] [Abstract][Full Text] [Related]
19. D-leucine microparticles as an excipient to improve the aerosolization performances of dry powders for inhalation.
Schoubben A; Vivani R; Paolantoni M; Perinelli DR; Gioiello A; Macchiarulo A; Ricci M
Eur J Pharm Sci; 2019 Mar; 130():54-64. PubMed ID: 30677523
[TBL] [Abstract][Full Text] [Related]
20. Powder, capsule and device: An imperative ménage à trois for respirable dry powders.
Schoubben A; Blasi P; Giontella A; Giovagnoli S; Ricci M
Int J Pharm; 2015 Oct; 494(1):40-8. PubMed ID: 26255220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]